ドンペリドン 化学特性,用途語,生産方法
外観
白色～うすい褐色, 結晶～粉末
溶解性
酢酸(100)に溶けやすく、メタノール及びエタノール(99.5)に溶けにくく、水にほとんど溶けない。
用途
ドンペリドンはこのD2受容体への拮抗作用により吐き気を抑え、上部消化管の運動機能を調整（促進）する。
用途
ドンペリドン（英: Domperidone）は、ドーパミン受容体拮抗薬の一つで、制吐薬、消化管機能改善薬として利用されている。
用途
ドパミンD2 受容体遮断作用 を示します。
効能
制吐薬, 消化管運動改善薬, ドパミンD2受容体拮抗薬
商品名
ナウゼリン (協和発酵キリン); ナウゼリン (協和発酵キリン); ナウゼリン (協和発酵キリン); ナウゼリン (協和発酵キリン); ナウゼリン (協和発酵キリン)
化学的特性
White or almost white powder.
使用
A novel peripheral dopamine receptor antagonist that does not cross the blood-brain barrier; anti-emetic. Domperidone(Motilium) is a dopamine blocker and an antidopaminergic reagent.
定義
ChEBI: 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used
s an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet
reparations.
世界保健機関（WHO）
Domperidone, a peripheral dopaminergic antagonist, was
introduced in 1979 for the symptomatic relief of acute nausea and vomiting. The
major manufacturer became aware that the injectable formulation was being used
in some countries in much higher doses than those recommended to combat
nausea and vomiting in cancer patients treated with cytostatic agents. Such use -
which was not in conformity with the approved indications - was associated with
cardiotoxicity, which in some cases was fatal, and the manufacturer decided to
withdraw the injectable dosage form from the market worldwide in January 1985.
Suppositories, tablets and a suspension remain available and the manufacturer
continues to supply the injection for the treatment of a named patient at the written
request of a doctor on the understanding that the appropriate dosage
recommendations will be followed.
生物活性
Peripheral dopamine D 2 -like receptor antagonist that does not readily cross the blood brain barrier. Displays gastroprokinetic and antiemetic properties; increases the frequency and duration of antral and duodenal contractions and protects from apomorphine-induced emesis (ED 50 values are 0.003 and 0.03 mg/kg for i.v. and oral administration respectively).
ドンペリドン 上流と下流の製品情報
原材料
準備製品